Xiaoyi Hu, Ping Yuan, Jun Chen, Shang Wang, Hui Zhao, Yaqin Wei, Jiaqi Fu, Fadong Chen, Hongyun Ruan, Wei Zhang, Yanli Zhou, Qiqi Wang, Xiaoling Xu, Kefu Feng, Jianzhou Guo, Sugang Gong, Ruifeng Zhang, Qinhua Zhao, Lan Wang
BACKGROUND: While the GRIPHON study and others have confirmed the efficacy and safety of selexipag with single, dual, and initial triple combination therapy for patients with pulmonary arterial hypertension (PAH), multicenters studies concerning diverse triple oral combination therapies based on selexipag are limited. HYPOTHESIS: This study was conducted to evaluate the effects of various sequential triple oral combination therapies on PAH outcomes. METHODS: A retrospective study was carried out involving 192 patients from 10 centers, who were receiving sequential triple oral combination therapy consisting of an endothelin receptor antagonist (ERA), a phosphodiesterase 5 inhibitor (PDE5i)/riociguat and selexipag...
February 2024: Clinical Cardiology